Corneal Collagen Cross-Linking for Infectious Keratitis: A Systematic Review and Meta-Analysis

Cornea

Volumn 35, Issue 1, 2016, Pages 62-71

  Papaioannou, Lamprini ^a   Miligkos, Michael ^b   Papathanassiou, Miltiadis ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

Author keywords

corneal collagen cross linking; infectious keratitis; photo activated riboflavin

Indexed keywords

ANTIBIOTIC AGENT; COLLAGEN; RIBOFLAVIN; VORICONAZOLE; CROSS LINKING REAGENT;

ACANTHAMOEBA; ACANTHAMOEBA KERATITIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL KERATITIS; BACTERIUM; COCHRANE LIBRARY; CORNEA ULCER; CROSS LINKING; FUNGUS; HERPES SIMPLEX VIRUS; HUMAN; INFECTIOUS KERATITIS; KERATITIS; KERATOMYCOSIS; KERATOPLASTY; MEDLINE; META ANALYSIS; MIXED INFECTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ULTRAVIOLET A RADIATION; VIRUS KERATITIS; CORNEA; EYE INFECTIONS, BACTERIAL; METABOLISM;

COLLAGEN; CORNEA; CROSS-LINKING REAGENTS; EYE INFECTIONS, BACTERIAL; HUMANS; KERATITIS;

EID: 84951905877     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0000000000000644     Document Type: Review

References (89)

1. Saeed A, D' Arcy F, Stack J, et al. Risk factors, microbiological findings, and clinical outcomes in cases of microbial keratitis admitted to a tertiary referral center in Ireland. Cornea. 2009;28:285-292.
2. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008;27:22-27.
3. Bertino J. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin Ophthalmol. 2009;3:507-521.
4. Mamalis N. The increasing problem of antibiotic resistance. J Cataract Refract Surg. 2007;33:1831-1832.
5. Hafezi F, Randleman JB. PACK-cxl: defining CXL for infectious keratitis. J Refract Surg. 2014;30:438-439.
6. Vinciquerra P, Albe E, Frueh BE, et al. Two-year corneal cross-linking results in patients younger than 18 years with documented progressive keratoconus. Am J Ophthalmol. 2012;154:520-526.
7. Suri K, Hammersmith KM, Nagra PK. Corneal collagen cross-linking: ectasia and beyond. Curr Opin Ophthalmol. 2012;23:280-287.
8. Hafezi F, Dejica P, Majo F. Modified corneal collagen crosslinking reduces corneal oedema and diurnal visual fluctuations in fuchs dystrophy. Br J Ophthalmol. 2010;94:660-661.
9. Spoerl E, Wollensak G, Seiler T. Increased resistance of crosslinked cornea against enzymatic digestion. Curr Eye Res. 2004;29:35-40.
10. Schilde T, Kohlhaas M, Spoerl E, et al. Enzymatic evidence of the depth dependence of stiffening on riboflavin/UVA treated corneas [in German]. Ophthalmologe. 2008;105:165-169.
11. Tsugita A, Okada Y, Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta. 1965;103:360-363.
12. Goodrich RP. The use of riboflavin for inactivation of pathogens in blood products. Vox Sang. 2000;78:211-215.
13. McAteer MJ, Tay-Goodrich B, Doane S. Photoinactivation of virus in packed red blood cell units using riboflavin and visible light. Transfusion. 2000;3(suppl 1):99S.
14. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011. Available at: www.cohrane-handbook.org.
15. Trikalinos TA, Trow P, Schmid CH. Simulation-based Comparison of Methods for Meta-analysis of Proportions and Rates. Methods Research Report. (Prepared by the Tufts Medical Center Evidence-based Practice Center Under Contract No. 290-2007-10055-I.) AHRQ Publication No. 13(14)-ehc084-ef. Rockville, MD: Agency for Healthcare Research and Quality; 2013. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
16. OpenMetaAnalyst: Powerful Open-source Software for Meta-analysis. Available at: http://www.cebm.brown.edu/open-meta/.
17. Iseli HP, Thiel MA, Hafezi F, et al. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008;27:590-594.
18. Micelli Ferrari T, Leozappa M, Lorusso M, et al. Escherichia coli keratitis treated with ultraviolet A/riboflavin corneal cross-linking: a case report. Eur J Ophthalmol. 2009;19:295-297.
19. Makdoumi K, Mortensen J, Crafoord S. Infectious keratitis treated with corneal crosslinking. Cornea. 2010;29:1353-1358.
20. Kozobolis V, Labiris G, Gkika M, et al. UV-a collagen cross-linking treatment of bullous keratopathy combined with corneal ulcer. Cornea. 2010;29:235-238.
21. Moren H, Malmsjo M, Mortensen J, et al. Riboflavin and ultraviolet a collagen crosslinking of the cornea for the treatment of keratitis. Cornea. 2010;29:102-104.
22. Khan YA, Kashiwabuchi RT, Martins SA, et al. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive acanthamoeba keratitis. Ophthalmology. 2011;118:324-331.
23. Anwar HM, El-Danasoury AM, Hashem AN. Corneal collagen crosslinking in the treatment of infectious keratitis. Clin Ophthalmol. 2011;5: 1277-1280.
24. Makdoumi K, Mortensen J, Sorkhabi O, et al. UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. Graefes Arch Clin Exp Ophthalmol. 2012;250:95-102.
25. Garduño-Vieyra L, Gonzalez-Sanchez CR, Hernandez-Da Mota SE. Ultraviolet-a light and riboflavin therapy for acanthamoeba keratitis: a case report. Case Rep Ophthalmol. 2011;2:291-295.
26. Panda A, Krishna SN, Kumar S. Photo-activated riboflavin therapy of refractory corneal ulcers. Cornea. 2012;31:1210-1213.
27. Price MO, Tenkman LR, Schrier A, et al. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg. 2012;28:706-713.
28. Müller L, Thiel MA, Kipfer-Kauer AI, et al. Corneal cross-linking as supplementary treatment option in melting keratitis: a case series. Klin Monbl Augenheilkd. 2012;229:411-415.
29. Kymionis GD, Kankariya VP, Kontadakis GA. Combined treatment with flap amputation, phototherapeutic keratectomy, and collagen crosslinking in severe intractable post-LASIK atypical mycobacterial infection with corneal melt. J Cataract Refract Surg. 2012;38:713-715.
30. Li Z, Jhanji V, Tao X, et al. Riboflavin/ultraviolet light-mediated crosslinking for fungal keratitis. Br J Ophthalmol. 2013;97:669-671.
31. Ferrari G, Iuliano L, Vigano M, et al. Impending corneal perforation after collagen cross-linking for herpetic keratitis. J Cataract Refract Surg. 2013;39:638-641.
32. Arance-Gil Á, Gutiérrez-Ortega ÁR, Villa-Collar C, et al. Corneal crosslinking for acanthamoeba keratitis in an orthokeratology patient after swimming in contaminated water. Cont Lens Anterior Eye. 2014;37:224-227.
33. Rosetta P, Vinciguerra R, Romano MR, et al. Corneal collagen crosslinking window absorption. Cornea. 2013;32:550-554.
34. Saʇlk A, Uçakhan OO, Kanpolat A. Ultraviolet A and riboflavin therapy as an adjunct in corneal ulcer refractory to medical treatment. Eye Contact Lens. 2013;39:413-415.
35. Sorkhabi R, Sedgipoor M, Mahdavifard A. Collagen cross-linking for resistant corneal ulcer. Int Ophthalmol. 2013;33:61-66.
36. Labiris G, Giarmoukakis A, Larin R, et al. Corneal collagen cross-linking in a late-onset graft infectious ulcer: a case report. J Med Case Rep. 2014; 8:180.
37. Said DG, Elalfy MS, Gatzioufas Z, et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology. 2014;121: 1377-1382.
38. Shetty R, Nagaraja H, Jayadev C, et al. Collagen crosslinking in the management of advanced non-resolving microbial keratitis. Br J Ophthalmol. 2014;98:1033-1035.
39. Skaat A, Zadok D, Goldich Y, et al. Riboflavin/UVA photochemical therapy for severe infectious keratitis. Eur J Ophthalmol. 2014;24:21-28.
40. Tabibian D, Richoz O, Riat A, et al. Accelerated photoactivated chromophore for keratitis-corneal collagen cross-linking as a first-line and sole treatment in early fungal keratitis. J Refract Surg. 2014;30:855-857.
41. Bamdad S, Malekhosseini H, Khosravi A. Ultraviolet A/riboflavin collagen cross-linking for treatment of moderate bacterial corneal ulcers. Cornea. 2015;34:402-406.
42. Hanet MS, Jamart J, Pinheiro Chaves A. Fluoroquinolones or fortified antibiotics for treating bacterial keratitis: systematic review and metaanalysis of comparative studies. Can J Ophthalmol. 2012;47:493-499.
43. McDonald EM, Ram FS, Patel DV, et al. Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. Br J Ophthalmol. 2014;98:1470-1477.
44. Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol. 2009;148:487-499.
45. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 1995;113:1257-1265.
46. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycincefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996;103:1854-1862.
47. Pavesio C, Morlet N, Allan B, et al. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. The Ofloxacin Study Group. Ophthalmology. 1997;104:1902-1909.
48. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye (Lond). 1999;13:744-747.
49. Erjongmanee S, Kasetsuwan N, Phusitphoykai N, et al. Clinical evaluation of ophthalmic lomefloxacin 0.3% in comparison with fortified cefazolin and gentamicin ophthalmic solutions in the treatment of presumed bacterial keratitis. J Med Assoc Thai. 2004;87:S83-S90.
50. Constantinou M, Daniell M, Snibson GR, et al. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis. A randomized clinical trial. Ophthalmology. 2007;114:1622-1629.
51. Shah VM, Tandon R, Satpathy G, et al. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers. Cornea. 2010;29:751-757.
52. Kasetsuwan N, Tanthuvanit P, Reinprayoon U. The efficacy and safety of 0.5% levofloxacin versus fortified cefazolin and amikacin ophthalmic solution for the treatment of suspected and culture proven cases of infectious bacterial keratitis: a comparative study. Asian Biomed. 2011;5: 77-83.
53. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991;112: 34S-47S.
54. Wilhelmus KR, Hyndiuk RA, Caldwell DR, et al. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment Bacterial Keratitis Study Group. Arch Ophthalmol. 1993;111:1210-1218.
55. Parks DJ, Abrams DA, Sarfarazi FA, et al. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol. 1993;115:471-477.
56. Gangopadhyay N, Daniell M, Weih L, et al. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophtalmol. 2000;84:378-384.
57. Ly CN, Pham JN, Badenoch PR, et al. Bacteria commonly isolated from keratitis specimens retain antibiotic susceptibility to fluoroquinolones and gentamicin plus cephalothin. Clin Exp Ophthalmol. 2006;34:44-45.
58. Kosrirukvongs P, Buranapongs W. Topical ciprofloxacin for bacterial corneal ulcer. J Med Assoc Thai. 2000;83:776-782.
59. Sampaio C, Alves M, Jose N, et al. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis [Avaliaçäo clínica do tratamento tópico das úlceras de córnea bacterianas com ciprofloxacina a 0,3 por cento]. Arq Bras Oftal. 1994;57:329-332.
60. Sharma N, Goel M, Bansal S, et al. Evaluation of moxifloxacin 0.5% in treatment of non perforated bacterial corneal ulcers: a randomized controlled trial. Ophthalmology. 2013;120:1173-1178.
61. Prajna NV, George C, Selvaraj S, et al. Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. Cornea. 2001;20:175-178.
62. Zhang M, Hu Y, Chen F. Clinical investigation of 0.3% levofloxacin eye drops on the treatment of cases with acute bacterial conjunctivitis and bacterial keratitis [in Chinese]. Yan Ke Xue Bao. 2000;16:146-148.
63. Larkin DF, Kilvington S, Dart JK. Treatment of acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology. 1992;99:185-191.
64. Ishibashi Y, Matsumoto Y, Kabata T, et al. Oral itraconazole and topical miconazole with debridement for acanthamoeba keratitis. Am J Ophthalmol. 1990;109:121-126.
65. Mathers W. Use of higher medication concentrations in the treatment of acanthamoeba keratitis. Arch Ophthalmol. 2006;124:923.
66. Seal D, Hay J, Kirkness C, et al. Successful medical therapy of acanthamoeba keratitis with topical chlorhexidine and propamidine. Eye (Lond). 1996;10:413-421.
67. Park DH, Palay DA, Daya SM, et al. The role of topical corticosteroids in the management of acanthamoeba keratitis. Cornea. 1997;16:277-283.
68. Hargrave SL, McCulley JP, Husseini Z. Results of a trial of combined propamidine isethionate and neomycin therapy for acanthamoeba keratitis. Brolene Study Group. Ophthalmology. 1999;106:952-957.
69. Lim N, Goh D, Bunce C, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of acanthamoeba keratitis. Am J Ophthalmol. 2008;145:130-135.
70. Makdoumi K, Bäckman A, Mortensen J, et al. Evaluation of antibacterial efficacy of photo-activated riboflavin using ultraviolet light (UVA). Graefes Arch Clin Exp Ophthalmol. 2010;248:207-212.
71. Schrier A, Greebel G, Attia H, et al. In vitro antimicrobial efficacy of riboflavin and ultraviolet light on staphylococcus aureus, methicillinresistant staphylococcus aureus, and pseudomonas aeruginosa. J Refract Surg. 2009;25:S799-S802.
72. Martins SA, Combs JC, Noguera G, et al. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008;49:3402-3408.
73. Kashiwabuchi RT, Carvalho FR, Khan YA, et al. Assessment of fungal viability after long-wave ultraviolet light irradiation combined with riboflavin administration. Graefes Arch Clin Exp Ophthalmol. 2013;251: 521-527.
74. Sauer A, Letscher-Bru V, Speeg-Schatz C, et al. In vitro efficacy of antifungal treatment using riboflavin/UV-A (365 nm) combination and amphotericin B. Invest Ophthalmol Vis Sci. 2010;51:3950-3953.
75. Galperin G, Berra M, Tau J, et al. Treatment of fungal keratitis from Fusarium infection by corneal cross-linking. Cornea. 2012;31:176-180.
76. Berra M, Galperín G, Boscaro G, et al. Treatment of acanthamoeba keratitis by corneal cross-linking. Cornea. 2013;32:174-178.
77. Kashiwabuchi RT, Carvalho FR, Khan YA. Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of acanthamoeba trophozoites. Invest Ophthalmol Vis Sci. 2011;52:9333-9338.
78. Matsumoto K. Role of bacterial proteases in pseudomonal and serratial keratitis. Biol Chem. 2004;385:1007-1016.
79. Iakovleva M, Kozel'tsev V. Proteolysis of collagen by several species of micromycetes and spore-forming bacteria [in Russian]. Prikl Biokhim Mikrobiol. 1994;30:121-126.
80. Wollensak G, Spoerl E, Wilsch M, et al. Keratocyte apoptosis after corneal collagen cross-linking using riboflavin/UVA treatment. Cornea. 2004;23:43-49.
81. Wang F. UVA/riboflavin-induced apoptosis in mouse cornea. Ophthalmologica. 2008;222:369-372.
82. Salomao MQ, Chaurasia SS, Sinha-Roy A, et al. Corneal wound healing after ultraviolet-A/riboflavin collagen crosslinking: a rabbit study. J Refract Surg. 2011;27:401-407.
83. Mencucci R, Marini M, Paladini I, et al. Effects of riboflavin/UVA corneal cross-linking on keratocytes and collagen fibres in human cornea. Clin Exp Ophthalmol. 2010;38:49-56.
84. Alam ZB, Otaki M, Furumai H, et al. Direct and indirect inactivation of microcystis aeruginosa by UV-radiation. Water Res. 2001;35:1008-1014.
85. Maisch T, Baier J, Franz B, et al. The role of singlet oxygen and oxygen concentration in photodynamic inactivation of bacteria. Proc Natl Acad Sci U S A. 2007;104:7223-7228.
86. Yoshimura M, Namura S, Akamatsu H, et al. Antimicrobial effects of phototherapy and photochemotherapy in vivo and in vitro. Br J Dermatol. 1996;135:528-532.
87. Xie L, Zhai H, Shi W. Penetrating keratoplasty for corneal perforations in fungal keratitis. Cornea. 2007;26:158-162.
88. Hill JC. Use of penetrating keratoplasty in acute bacterial keratitis. Br J Ophthalmol. 1986;70:502-506.
89. Kymionis GD, Portaliou DM, Bouzoukis DI, et al. Herpetic keratitis with iritis after corneal crosslinking with riboflavin and ultraviolet A for keratoconus. J Cataract Refract Surg. 2007;33:1982-1984.